Indication
For the treatment of postmenopausal women, and men, with oestrogen receptor-positive (ER+), human epidermal factor receptor 2-negative (HER2-), locally advanced or metastatic (m) breast cancer (BC) with an activating oestrogen receptor 1 (ESR1) mutation (mut) who have disease progression following at least one line of endocrine therapy (ET) including a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
Medicine details
- Medicine name:
- elacestrant (Korserdu)
- SMC ID:
- SMC2933
- Pharmaceutical company
- Menarini Stemline
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC